Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
POSTED
05-10-22
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
POSTED
11-03-21
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
POSTED
01-12-21
Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy
POSTED
06-02-20
Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report
June 2, 2020 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report
POSTED
02-14-20
International Childhood Cancer Day Announcement: Global Hope, Teva and Direct Relief Partner to Bring Medicines to Help Improve the Lives of Children With Cancer in Africa
Global HOPE (Hematology-Oncology Pediatric Excellence), a program of Texas Children’s Hospital, Teva Pharmaceutical Industries Ltd. and Direct Relief announced today a donation partnership that will provide access to medications in sub-Saharan Africa—where an overwhelming majority of pediatric ca...
POSTED
07-17-18
Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report
A message from our CEO, Kåre Schultz
Teva has a rich history of providing innovative, high-quality generic and specialty drugs and health solutions to patients around the world every day. Since joining the company late last year, I’ve been motivated by the opportunity to advance thi...
POSTED
09-18-17
New Initiative Creates Scalable Solutions to Improve Care of Patients With Multiple Chronic Conditions
Today, two leading private sector groups announced a partnership to create scalable solutions to improve patient and health system care for Multiple Chronic Conditions.
The initiative was announced to an audience of public health leaders at the World Economic Forum’s (WEF) Sustainable Deve...
POSTED
09-14-17
Teva Continues to Advance Care for Society’s Health and Wellbeing; 2016 Social Impact Report Released
In 2016, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) engaged more than 300,000 people in 35 countries in programs aimed to help and empower patients as they deal with their illnesses.
These patient support programs are among the outcomes of broader efforts...
POSTED
01-26-17
Teva Announces 2017-18 U.S. Community Partner Organizations
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the U.S. organizations selected as part of Teva’s 2017-18 Community Partnership Program. Now in its fourth year, this exciting Teva program provides charitable funding and employee volunteers to qualified local organizations that s...
POSTED
09-19-16
Teva Pharmaceuticals Accepting Applications for the 2017-18 Community Partnership Program through October 21, 2016
Teva Pharmaceuticals is now accepting entries for the 2017-18 Teva Community Partnership Program. Now in its third year, this exciting Teva program provides charitable funding and employee volunteers to qualified local organizations that support patients and their caregivers and...
